161 related articles for article (PubMed ID: 34254534)
1. Outcomes after retreatment with MAPK inhibitors and immune checkpoint inhibitors in melanoma patients.
Persa OD; Mauch C
Future Oncol; 2021 Oct; 17(29):3809-3817. PubMed ID: 34254534
[TBL] [Abstract][Full Text] [Related]
2. Decreased survival in patients treated by chemotherapy after targeted therapy compared to immunotherapy in metastatic melanoma.
Mangin MA; Boespflug A; Maucort Boulch D; Vacheron CH; Carpentier I; Thomas L; Dalle S
Cancer Med; 2021 May; 10(10):3155-3164. PubMed ID: 33932099
[TBL] [Abstract][Full Text] [Related]
3. Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.
Hilbers ML; Dimitriou F; Lau P; Bhave P; McArthur GA; Zimmer L; Kudura K; Gérard CL; Levesque MP; Michielin O; Dummer R; Cheng PF; Mangana J
Eur J Cancer; 2021 Oct; 156():149-163. PubMed ID: 34454317
[TBL] [Abstract][Full Text] [Related]
4. The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients.
Zaremba A; Eggermont AMM; Robert C; Dummer R; Ugurel S; Livingstone E; Ascierto PA; Long GV; Schadendorf D; Zimmer L
Eur J Cancer; 2021 Sep; 155():268-280. PubMed ID: 34392069
[TBL] [Abstract][Full Text] [Related]
5. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
[TBL] [Abstract][Full Text] [Related]
6. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis.
Li M; Sack JS; Rahma OE; Hodi FS; Zucker SD; Grover S
Cancer; 2020 Dec; 126(23):5088-5097. PubMed ID: 32888341
[TBL] [Abstract][Full Text] [Related]
7. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitors rechallenge in urological tumors: An extensive review of the literature.
Bimbatti D; Maruzzo M; Pierantoni F; Diminutto A; Dionese M; Deppieri FM; Lai E; Zagonel V; Basso U
Crit Rev Oncol Hematol; 2022 Feb; 170():103579. PubMed ID: 35007699
[TBL] [Abstract][Full Text] [Related]
9. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
10. Retreatment With Immune Checkpoint Inhibitors After a Severe Immune-Related Hepatitis: Results From a Prospective Multicenter Study.
Riveiro-Barciela M; Barreira-Díaz A; Callejo-Pérez A; Muñoz-Couselo E; Díaz-Mejía N; Díaz-González Á; Londoño MC; Salcedo MT; Buti M
Clin Gastroenterol Hepatol; 2023 Mar; 21(3):732-740. PubMed ID: 35487453
[TBL] [Abstract][Full Text] [Related]
11. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.
Knispel S; Gassenmaier M; Menzies AM; Loquai C; Johnson DB; Franklin C; Gutzmer R; Hassel JC; Weishaupt C; Eigentler T; Schilling B; Schummer P; Sirokay J; Kiecker F; Owen CN; Fleischer MI; Cann C; Kähler KC; Mohr P; Bluhm L; Niebel D; Thoms KM; Goldinger SM; Reinhardt L; Meier F; Berking C; Reinhard R; Susok L; Ascierto PA; Drexler K; Pföhler C; Tietze J; Heinzerling L; Livingstone E; Ugurel S; Long GV; Stang A; Schadendorf D; Zimmer L
Eur J Cancer; 2021 May; 148():61-75. PubMed ID: 33735811
[TBL] [Abstract][Full Text] [Related]
12. MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint Inhibitors.
Motti ML; Minopoli M; Di Carluccio G; Ascierto PA; Carriero MV
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32604720
[TBL] [Abstract][Full Text] [Related]
13. Treatment Following Progression in Metastatic Melanoma: the State of the Art from Scientific Literature to Clinical Need.
Serra F; Barruscotti S; Dominioni T; Zuccarini A; Pedrazzoli P; Chiellino S
Curr Oncol Rep; 2021 May; 23(7):84. PubMed ID: 34009481
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Immune Checkpoint Inhibitor (ICI) Rechallenge in Advanced Melanoma Patients' Responders to a First Course of ICI: A Multicenter National Retrospective Study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC).
Nardin C; Hennemann A; Diallo K; Funck-Brentano E; Puzenat E; Heidelberger V; Jeudy G; Samimi M; Lesage C; Boussemart L; Peuvrel L; Rouanet J; Brunet-Possenti F; Gerard E; Seris A; Jouary T; Saint-Jean M; Puyraveau M; Saiag P; Aubin F
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509227
[TBL] [Abstract][Full Text] [Related]
15. Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study.
Valpione S; Carlino MS; Mangana J; Mooradian MJ; McArthur G; Schadendorf D; Hauschild A; Menzies AM; Arance A; Ascierto PA; Di Giacomo A; de Rosa F; Larkin J; Park JJ; Goldinger SM; Sullivan RJ; Xu W; Livingstone E; Weichenthal M; Rai R; Gaba L; Long GV; Lorigan P
Eur J Cancer; 2018 Mar; 91():116-124. PubMed ID: 29360604
[TBL] [Abstract][Full Text] [Related]
16. Impact of prior treatment with immune checkpoint inhibitors on dacarbazine efficacy in metastatic melanoma.
Bouchereau S; Chaplain L; Fort M; Beauchet A; Sidibé T; Chapalain M; Gonzalez-Lara L; Longvert C; Blom A; Saiag P; Funck-Brentano E
Br J Cancer; 2021 Sep; 125(7):948-954. PubMed ID: 34262147
[TBL] [Abstract][Full Text] [Related]
17. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
[TBL] [Abstract][Full Text] [Related]
18. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
[TBL] [Abstract][Full Text] [Related]
19. Risk Factors for Relapse after Intentional Discontinuation of Immune Checkpoint Inhibitors in Melanoma Patients.
Persa OD; Schatton K; Rübben A; Berking C; Erdmann M; Schlaak M; Mauch C; Steeb T
J Immunother; 2021 Jul-Aug 01; 44(6):239-241. PubMed ID: 34028389
[TBL] [Abstract][Full Text] [Related]
20. In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma.
Babačić H; Lehtiö J; Pico de Coaña Y; Pernemalm M; Eriksson H
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
